Cargando…
Effect of Adjuvant and Palliative Chemotherapy in Large Cell Neuroendocrine Carcinoma of the Lung: A Systematic Review and Meta-Analysis
SIMPLE SUMMARY: Adjuvant chemotherapy revealed a better outcome than surgery only, but there was no statistical difference in patients with stage IA. The small cell lung cancer regimen (SCLC) was frequently selected in adjuvant chemotherapy. The SCLC regimen showed better survival than the non-SCLC...
Autores principales: | Chen, Hao, Ishihara, Masashi, Horita, Nobuyuki, Kazahari, Hiroki, Ochiai, Ryusuke, Tanzawa, Shigeru, Honda, Takeshi, Ichikawa, Yasuko, Watanabe, Kiyotaka, Seki, Nobuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657002/ https://www.ncbi.nlm.nih.gov/pubmed/34885057 http://dx.doi.org/10.3390/cancers13235948 |
Ejemplares similares
-
Effectiveness of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Malignancy-Related Ascites: A Systematic Review and Meta-Analysis
por: Chen, Hao, et al.
Publicado: (2021) -
Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019) -
Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Ishihara, Masashi, et al.
Publicado: (2021) -
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019) -
Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush
por: Seki, Nobuhiko, et al.
Publicado: (2019)